Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.

Conclusion: Our study provides weak evidence to support the use of genetic variation in ABCB1, SLCO1B1, CYP3A4, and CYP3A5 as biomarkers of breast tumor response to simvastatin. Validation of these findings within adjuvant clinical trials is encouraged.
PMID: 32351149 [PubMed - as supplied by publisher]

Source: Acta Oncologica - April 29, 2020 Category: Cancer & Oncology Authors: Ahern TP, Damkier P, Feddersen S, Kjærsgaard A, Lash TL, Hamilton-Dutoit S, Lythjohan CB, Ejlertsen B, Christiansen PM, Cronin-Fenton DP Tags: Acta Oncol Source Type: research